Company Summary
Search
Home Page
 
Immunovaccine Inc. 
Listed Company 
Current   Past  
Fiscal Year EndCompany StatusExempt Flag
December 31TradingN
Board of Directors
NamePosition
Albert Scardino  Non-Executive chairman
  Director of the Board
Alfred (Fred) A. Smithers  Director of the Board
Brad Thompson  Director of the Board
James Willis Hall  Director of the Board
Marc Mansour  Director of the Board
Not Applicable (None)  President
Wade K. Dawe  Director of the Board
Wayne Pisano  Director of the Board
Incorporation Locations
Inc. DateExpiry DateCountryRegionDescription
18/May/2007  Canada   
Exchange Filing Office
Location
Montreal Regional Service Office
Business Type(s)
Primary/SecondaryBusiness TypeDetails
Primary  Research and Development in the Physical, Engineering and Life Sciences  News Release June 11, 2014-Immunovaccine Inc. develops cancer immunotherapies and infectious disease vaccines based on the Company's DepoVax? platform, a patented formulation that provides controlled and prolonged exposure of antigens and adjuvant to the immune system. Immunovaccine has advanced two T cell activation therapies for cancer through Phase I human clinical trials. Lead cancer vaccine therapy, DPX-Survivac, is expected to enter Phase II clinical studies in both ovarian cancer and glioblastoma (brain cancer). The Company is also advancing an infectious disease pipeline including innovative vaccines for respiratory syncytial virus (RSV) and anthrax. 
Securities
SymbolSecurity NameMarketStatus
IMVImmunovaccine Inc.TSX VentureTRADING
Name HistoryFromTo
Immunovaccine Inc.5/Oct/2009Present
Company Facts Reconciliation
SubjectDate Returned
Fall 2014 CFRNot Received
Associations
Auditing Firm:  PricewaterhouseCoopers LLP
Sponsor:  Macquarie Private Wealth Inc.
Transfer Agent:  Computershare Investor Services Inc.
Latest Information
TypeDateTitle
News Releases  19/Nov/2014  NEWS RELEASE - HEALTH CANADA CLEARS IMMUNOVACCINE TO CONDUCT PH[MARKET NEWS]
    NEWS RELEASE - HEALTH CANADA CLEARS IMMUNOVACCINE TO CONDUCT PHASE II CLINICAL TRIAL OF DPX-SURVIVAC IN RECURRENT LYMPHOMA[MARKETWIRE]
    NEWS RELEASE - IMMUNOVACCINE ANNOUNCES FINANCIAL RESULTS FOR QUARTER ENDED SEPTEMBER 30 2014[MARKETWIRE]
Bulletins  17/Sep/2014  Prospectus-Share Offering
Meetings and Public Filings  Information on financial statements, public filings and corporate meetings for all Canadian public companies can be found at www.sedar.com
Property Locations
(not available)

* Historical Data